Ovarian cancer is the second deadliest gynecological worldwide as most women present with advanced-stage disease. There is also no strong consensus as to which women will benefit most from neoadjuvant chemotherapy, but it is usually preserved for the poor candidates for primary surgery due to either the location or severity of the disease or medical comorbidity. In our study, we aimed to evaluate the parameters that predict the response to neoadjuvant chemotherapy. We also aimed to evaluate the prognostic and clinical value of pre-surgical assessment of KI-67 protein, Tumor infiltrating lymphocytes and histological type and grade in drawing a set of characteristics of patients who will have the best response to neoadjuvant chemotherapy. The methodology was retrospective review of patients who were diagnosed with locally advanced ovarian cancer using the cancer registration database in Alshatby University Maternity Hospital and Alexandria University Clinical Oncology department. The patients had NACT followed by staging laparotomy and they were followed up for two years afterwards. The results showed significant association between good response to chemotherapy and younger age, lower FIGO Stage, Higher Ca-125, Higher Grade Serous carcinomas, Higher Ki 67 and the presence tumor infiltrating lymphocytes. We also validated and refined the Chemotherapy Response Score CRS and found it significantly associated with progression free survival and Overall survival. Our conclusion was: CRS was a valid tool to evaluate response to NACT. There are some characteristics that can predict response to NACT. However, larger multicenter and prospective studies are required to confirm these associations.